Competitor Analysis: Therapeutic Proteins Biosimilars, Biobetters & Biosuperiors

Transcription

1 Brochure More information from Competitor Analysis: Therapeutic Proteins Biosimilars, Biobetters & Biosuperiors Description: The new Competitive Intelligence Report Therapeutic Proteins Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets: - Erythropoietin (EPO) & Erythr - G-CSF & GM-CSF - Thrombopoietin & Thrombopoies - Interferon - Insulin - Coagulation Factors - Human Growth Hormone (hgh) - FSH, hcg and LH: Therapeutic - Thrombolytics & Fibrinolytics - Enzyme Replacement Therapies Territories covered are the major pharmaceutical markets North America, Europe and Japan, as well as South Korea, India, China and other countries in Latin America, Africa and Australasia. With more than US$ 50 bln in sales, therapeutic proteins represent a major category of pharmaceutical products with established therapeutic value and high economic attractiveness. As more and more of the branded products are running out of patent protection and regulatory agencies are providing better guidance, development of biosimilar versions as well as of improved next generation versions are a highly attractive goal for pharmaceutical and biotechnology as well as technology focused companies. This report includes a compilation of current active projects in research and development of biosimilar and novel biobetter/biosuperior therapeutic proteins as well as non-protein based competitor products and an overview of approved products in regulated and less regulated markets. Competitor projects are listed in a tabular format providing Information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage, - additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Contents: 1) Erythropoiesis Stimulating Agents (ESA) First generation epoetins in regulated markets Second generation epoetins in regulated markets Epoetin biosimilars in regulated markets Darbepoetin biosimilars in regulated markets

2 Next generation biologic Eythropoiesis Stimulating Agents (ESA) in regulated markets Next generation small molecule Erythropoiesis Stimulating Agents First generation EPO in less regulated markets (Latin America; Africa; Asia; RoW) Darbepoietin biosimilars in less regulated markets Next generation biologic ESAs in less regulated markets 2) G-CSF and GM-CSF 2012 Sales of Branded G-CSF Products in Regulated Markets 1st Generation Branded G-CSF Products in Regulated Markets Biosimilar 1st Generation G-CSF Products in Regulated Markets Next Generation Branded G-CSF Products in Regulated Markets Biosimilar Next Generation G-CSF Products in Regulated Markets 1st Generation G-CSF Products in Non-Regulated Markets: India 1st Generation G-CSF Products in Non-Regulated Markets: China & Taiwan 1st Generation G-CSF Products in Non-Regulated Markets Korea 1st Generation G-CSF Products in Non-Regulated Markets Latin America 1st Generation G-CSF Products in Non-Regulated Markets: Other Territories Next Generation G-CSF Products in Non-Regulated Markets 1st and Next Generation GM-CSF Products in Regulated Markets 1st and Next Generation GM-CSF Products in Non-Regulated Markets 3 ) Thrombopoiesis-Stimulating Agents (TPO; IL-11) Thrombopoietin receptor (TPO-R) activators Interleukin-11 (IL-11) receptor activators Small molecule TPO-R Agonists Corporate TPO/IL-11 Receptor Agonist Product Portfolios and R&D Pipelines 4 ) Interferon a) INTERFERON alpha Interferon alpha sales 2012 of branded products in regulated markets 1st generation Interferon alpha-2a in regulated markets 1st generation Interferon alpha-2a in non-regulated markets Next generation Interferon alpha-2a in regulated markets Next generation Interferon alpha-2a in non-regulated markets and biosimilars 1st generation Interferon alpha-2b in regulated markets 1st generation Interferon alpha-2b in non-regulated markets and biosimilars Next generation Interferon alpha-2b in regulated markets Next generation Interferon alpha-2b in non-regulated markets and biosimilars Other Interferon alpha sub-types Interferon alpha with not specified sub-type 1/2 Purified natural human interferon alpha b) Consensus INTERFERONs c) INTERFERON beta Interferon beta sales 2012 of branded products in regulated markets 1st generation Interferon beta-1a in regulated markets 1st generation Interferon beta-1a in non-regulated markets and biosimilars 1st generation Interferon beta-1b in regulated markets 1st generation Interferon beta-1b in non-regulated markets and biosimilars 1st generation Interferon beta with not disclosed sub-type Next generation Interferon beta in regulated markets Purified natural human interferon beta d) INTERFERON gamma e) Other INTERFERONs

3 5 ) Insulin 2012 Sales of branded recombinant human insulins in regulated markets 2012 Sales of branded short-acting recombinant human insulin analogs in regulated markets 2012 Sales of branded long-acting recombinant human insulin analogs in regulated markets Rhu insulin (2nd generation) in regulated markets Biosimilar rhu insulin (2nd generation) in regulated markets Rhu insulin analogs (3rd generation) in regulated markets Biosimilar rhu insulin analogs (3rd generation) in regulated markets Ultra-long acting rhu insulin formulations and insulin analogs (4th generation) Ultra-fast acting rhu insulin formulations and insulin analogs (4th generation) Combinations of modern basal and prandial insulin & analogs (4th generation) Combinations of insulin & GLP-1 agonist (4th generation) Other combinations with insulin Oral and Transbuccal Insulins (5th generation) Inhaled and transdermal insulin Novel approaches for insulin therapy Rhu insulin (2nd generation) in non-regulated markets: India Rhu insulin (2nd generation) in non-regulated markets: China Rhu insulin (2nd generation) in non-regulated markets: Other Territories Modern insulin analogs (3rd generation) in non-regulated markets 6 ) Coagulation Factors Sales of Recombinant Coagulation Factors for Hemophilia in 2012 Coagulation Factor VIII Coagulation Factor IX Coagulation Factor VII Coagulation Factors for Willebrand Disease Fibrinogen Factors XI, X and XIII Alternative Procoagulants & Adjuncts Human Plasma-Derived Prothrombin Complex Concentrates Gene Therapy of Hemophilia Topical Human Plasma-Derived Fibrinogen and Thrombin Products Topical Plasma-Derived Thrombin Products Topical Recombinant Human Factor II (Prothrombin) Alternative Topical Hemostats 7 ) Human Growth Hormone (hgh) 2012 Sales of Branded Somatropin Products in Regulated Markets 2012 Sales of Selected Somatropin Products in Non-Regulated Markets 1st Generation: Somatropin in Regulated Markets 1st Generation: Biosimilar Somatropin in Regulated Markets 2nd Generation: Injectable Somatropin in Slow-release Formulation in Regulated Markets 2nd Generation: Injectable Long-acting Somatropin in Regulated Markets 2nd Generation: Injection-Free Somatropin in Regulated Markets 1st Generation: Somatropin Products in Non-Regulated Markets 2nd Generation: Injectable Long-Acting Somatropin Products in Non-Regulated Markets 8 ) FSH, hcg and LH - Assisted Reproductive Technology (ART) Urinary FSH-Containing Products: Menotropins Recombinant Menotropins 1st Generation Purified Human Urinary FSH 2nd Generation Recombinant Human FSH Biosimilar Recombinant Human FSH 2nd Generation Rhu FSH in Non-Regulated Markets 3rd Generation Rhu FSH Purified Urinary Human Choriogonadotropin (hcg) Recombinant Human Choriogonadotropin (rhcg) Recombinant Human Luteinizing Hormone (rhlh)

4 hcg Receptor Agonist 9 ) Thrombolytics & Fibrinolytics Non-fibrin selective (1st generation) Fibrinolytics Fibrin selective wild-type t-pa-based Fibrinolytics Fibrin selective engineered t-pa-based Fibrinolytics Non-t-PA-based Fibrinolytics Plasmin-based Fibrinolytics Adjunctive therapy to Fibrinolytics Biosimilar Thrombolytics and Fibrinolytics in Non-Regulated Markets 10) Enzyme Replacement Therapies Gaucher Disease Fabry Disease Pompé Disease Hunter Disease (MPS II) Niemann Pick Diseases Mucopolysaccharidosis I (MPS I) San Filippo Syndrome (MPS IIIA) Morquio Syndrome (MPS IVA) Mucopolysaccharidosis VI (MPS VI) Tay-Sachs Disease Chronic Deficiency of Adenosine Deaminase Phenylketonuria / Hyperphenylalaninemia Other Enzyme Replacement Therapies Exocrine Pancreatic Insufficiency: Porcine-Derived ERT Exocrine Pancreatic Insufficiency: Recombinant ERT Others Ordering: Order Online - Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.

5 Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to (from USA) or (from Rest of World). If you have any questions please visit Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Web Address: Office Code: Competitor Analysis: Therapeutic Proteins Biosimilars, Biobetters & Biosuperiors SC Product Formats Please select the product formats and quantity you require: Electronic (PDF) - Single User: Electronic (PDF) - Enterprisewide: Electronic (PDF) - Site License: Quantity USD 1763 USD 5290 USD 3527 Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free accounts when ordering (e.g. Yahoo, Hotmail, AOL)

6 Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address ULSBIE2D IE78ULSB Ulster Bank, Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at Please fax this form to: (646) or (646) From USA or From Rest of World